445 related articles for article (PubMed ID: 10326868)
41. Somatic mutation of the tuberous sclerosis (Tsc2) tumor suppressor gene in chemically induced rat renal carcinoma cell.
Urakami S; Tokuzen R; Tsuda H; Igawa M; Hino O
J Urol; 1997 Jul; 158(1):275-8. PubMed ID: 9186374
[TBL] [Abstract][Full Text] [Related]
42. Should endolymphatic sac tumors be considered part of the von Hippel-Lindau complex? Pathology case report.
Tibbs RE; Bowles AP; Raila FA; Fratkin JD; Hutchins JB
Neurosurgery; 1997 Apr; 40(4):848-55; discussion 855. PubMed ID: 9092862
[TBL] [Abstract][Full Text] [Related]
43. Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma.
Gao W; Li W; Xiao T; Liu XS; Kaelin WG
Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1027-1032. PubMed ID: 28082722
[TBL] [Abstract][Full Text] [Related]
44. Role of exon 2-encoded beta -domain of the von Hippel-Lindau tumor suppressor protein.
Bonicalzi ME; Groulx I; de Paulsen N ; Lee S
J Biol Chem; 2001 Jan; 276(2):1407-16. PubMed ID: 11024059
[TBL] [Abstract][Full Text] [Related]
45. Mutations in the VHL gene from potassium bromate-induced rat clear cell renal tumors.
Shiao YH; Kamata SI; Li LM; Hooth MJ; DeAngelo AB; Anderson LM; Wolf DC
Cancer Lett; 2002 Dec; 187(1-2):207-14. PubMed ID: 12359370
[TBL] [Abstract][Full Text] [Related]
46. Detection of von Hippel-Lindau disease gene mutations in paraffin-embedded sporadic renal cell carcinoma specimens.
Zhuang Z; Gnarra JR; Dudley CF; Zbar B; Linehan WM; Lubensky IA
Mod Pathol; 1996 Aug; 9(8):838-42. PubMed ID: 8871925
[TBL] [Abstract][Full Text] [Related]
47. Downregulation of Cap43 gene by von Hippel-Lindau tumor suppressor protein in human renal cancer cells.
Masuda K; Ono M; Okamoto M; Morikawa W; Otsubo M; Migita T; Tsuneyoshi M; Okuda H; Shuin T; Naito S; Kuwano M
Int J Cancer; 2003 Jul; 105(6):803-10. PubMed ID: 12767066
[TBL] [Abstract][Full Text] [Related]
48. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma.
Igarashi H; Esumi M; Ishida H; Okada K
Cancer; 2002 Jul; 95(1):47-53. PubMed ID: 12115316
[TBL] [Abstract][Full Text] [Related]
49. Regulation of E2F1 by the von Hippel-Lindau tumour suppressor protein predicts survival in renal cell cancer patients.
Mans DA; Vermaat JS; Weijts BG; van Rooijen E; van Reeuwijk J; Boldt K; Daenen LG; van der Groep P; Rowland BD; Jans JJ; Roepman R; Voest EE; van Diest PJ; Verhaar MC; de Bruin A; Giles RH
J Pathol; 2013 Sep; 231(1):117-29. PubMed ID: 23744542
[TBL] [Abstract][Full Text] [Related]
50. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer.
Smith K; Gunaratnam L; Morley M; Franovic A; Mekhail K; Lee S
Cancer Res; 2005 Jun; 65(12):5221-30. PubMed ID: 15958567
[TBL] [Abstract][Full Text] [Related]
51. Mutations in the von Hippel-Lindau (VHL) gene refine differential diagnostic criteria in renal cell carcinoma.
Barnabas N; Amin MB; Pindolia K; Nanavati R; Amin MB; Worsham MJ
J Surg Oncol; 2002 May; 80(1):52-60. PubMed ID: 11967908
[TBL] [Abstract][Full Text] [Related]
52. Intratumoral heterogeneity of von Hippel-Lindau gene deletions in renal cell carcinoma detected by fluorescence in situ hybridization.
Moch H; Schraml P; Bubendorf L; Richter J; Gasser TC; Mihatsch MJ; Sauter G
Cancer Res; 1998 Jun; 58(11):2304-9. PubMed ID: 9622063
[TBL] [Abstract][Full Text] [Related]
53. VHL and FHIT locus loss of heterozygosity is common in all renal cancer morphotypes but differs in pattern and prognostic significance.
Velickovic M; Delahunt B; Störkel S; Grebem SK
Cancer Res; 2001 Jun; 61(12):4815-9. PubMed ID: 11406557
[TBL] [Abstract][Full Text] [Related]
54. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway.
Qi H; Ohh M
Cancer Res; 2003 Nov; 63(21):7076-80. PubMed ID: 14612498
[TBL] [Abstract][Full Text] [Related]
55. Genetic basis of cancer of the kidney: disease-specific approaches to therapy.
Linehan WM; Vasselli J; Srinivasan R; Walther MM; Merino M; Choyke P; Vocke C; Schmidt L; Isaacs JS; Glenn G; Toro J; Zbar B; Bottaro D; Neckers L
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6282S-9S. PubMed ID: 15448018
[TBL] [Abstract][Full Text] [Related]
56. Analysis of aberrant methylation of the VHL gene by transgenes, monochromosome transfer, and cell fusion.
Kuzmin I; Geil L; Ge H; Bengtsson U; Duh FM; Stanbridge EJ; Lerman MI
Oncogene; 1999 Oct; 18(41):5672-9. PubMed ID: 10523847
[TBL] [Abstract][Full Text] [Related]
57. Von Hippel-Lindau disease and sporadic renal cell carcinoma.
Zbar B
Cancer Surv; 1995; 25():219-32. PubMed ID: 8718521
[TBL] [Abstract][Full Text] [Related]
58. Renal cell carcinoma of end-stage renal disease: a histopathologic and molecular genetic study.
Hughson MD; Schmidt L; Zbar B; Daugherty S; Meloni AM; Silva FG; Sandberg AA
J Am Soc Nephrol; 1996 Nov; 7(11):2461-8. PubMed ID: 8959640
[TBL] [Abstract][Full Text] [Related]
59. The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2'-deoxycytidine.
Alleman WG; Tabios RL; Chandramouli GV; Aprelikova ON; Torres-Cabala C; Mendoza A; Rogers C; Sopko NA; Linehan WM; Vasselli JR
Clin Cancer Res; 2004 Oct; 10(20):7011-21. PubMed ID: 15501981
[TBL] [Abstract][Full Text] [Related]
60. Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma.
Grabmaier K; A de Weijert MC; Verhaegh GW; Schalken JA; Oosterwijk E
Oncogene; 2004 Jul; 23(33):5624-31. PubMed ID: 15184875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
